You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer
|
|---|---|
| Published in |
Breast Cancer Research, March 2014
|
| DOI | 10.1186/bcr3634 |
| Pubmed ID | |
| Authors |
Jasmeet Chadha Singh, Yelena Novik, Stacey Stein, Matthew Volm, Marlene Meyers, Julia Smith, Coral Omene, James Speyer, Robert Schneider, Komal Jhaveri, Silvia Formenti, Victoria Kyriakou, Benson Joseph, Judith D Goldberg, Xiaochun Li, Sylvia Adams, Amy Tiersten |
| Abstract |
Rapamycin acts synergistically with platinum agents to induce apoptosis and inhibit proliferation in breast cancer cell lines. Combination of everolimus also known as RAD001 (oral mammalian target of rapamycin (mTOR) inhibitor) and carboplatin may have activity in metastatic triple-negative breast cancer (TNBC). |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Science communicators (journalists, bloggers, editors) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 83 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 1% |
| Unknown | 82 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 14 | 17% |
| Student > Ph. D. Student | 12 | 14% |
| Researcher | 10 | 12% |
| Student > Bachelor | 6 | 7% |
| Other | 4 | 5% |
| Other | 13 | 16% |
| Unknown | 24 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 21 | 25% |
| Biochemistry, Genetics and Molecular Biology | 14 | 17% |
| Agricultural and Biological Sciences | 8 | 10% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 5% |
| Psychology | 2 | 2% |
| Other | 7 | 8% |
| Unknown | 27 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 April 2014.
All research outputs
#18,370,767
of 22,753,345 outputs
Outputs from Breast Cancer Research
#1,593
of 1,894 outputs
Outputs of similar age
#163,760
of 226,159 outputs
Outputs of similar age from Breast Cancer Research
#19
of 27 outputs
Altmetric has tracked 22,753,345 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,894 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.9. This one is in the 7th percentile – i.e., 7% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 226,159 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 14th percentile – i.e., 14% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 27 others from the same source and published within six weeks on either side of this one. This one is in the 11th percentile – i.e., 11% of its contemporaries scored the same or lower than it.